Compare D R Horton Inc (DHI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Moderna, Inc. — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 2.1× D R Horton Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Moderna, Inc. for 59 Days on average.
| DHI | MRNA | |
|---|---|---|
Market Cap | $37.99B | $78.65B |
Volume | 2,974,460 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $203.46 |
52-Week Low | $132.53 | $22.36 |
Typical Hold Time | 46 Days | 59 Days |
Enterprise Value | $43.09B | $74.80B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% today, but faces a bearish technical outlook with resistance at $137. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue declined to $34.25B in 2025, and net income margin compressed to 9.15%. Analysts maintain a buy consensus with a $156.57 target, but rising mortgage rates and housing market weakness pose headwinds.
The stock offers value with a P/E of 12.95 and strong cash flow, but investor sentiment is cautious due to macroeconomic risks. Near-term performance hinges on Q3 earnings and interest rate trends. The current price near the low end of the target range suggests limited downside if fundamentals hold.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
